ABBV

Abbvie Inc

Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.

Current Price

$212.30

-0.68%

GoodMoat Value

$132.47

37.6% overvalued

Profile

Valuation (TTM)

Market Cap$375.38B

P/E103.27

EV$424.43B

P/B—

Shares Out1.77B

P/Sales5.98

Revenue$62.82B

EV/EBITDA26.36

Abbvie Inc (ABBV) Valuation

ABBV Fair Value Estimate

$132.4737.6% overvalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

ABBV Valuation Metrics

FCF$17.82B

FCF Growth Rate5.70%

EPS Growth (CAGR)-9.87%

WACC10.00%

Fair Value Models

Graham Number, PEG-based, and Earnings-based models

View Fair Value →

ABBV Valuation & Fair Value Analysis

Abbvie Inc (ABBV) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for Abbvie Inc is $132.47. The current stock price is $212.30, suggesting the stock is 60.3% overvalued.

The price-to-earnings (P/E) ratio is 103.27. Price-to-sales ratio is 5.98. Enterprise value to EBITDA is 26.36. PEG ratio is -2.25.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Abbvie Inc's intrinsic value.